Alpine Immune Sciences, Inc. (ALPN) Q4 Earnings and Revenues Beat Estimates

分组1 - Alpine Immune Sciences, Inc. reported quarterly earnings of $0.15 per share, exceeding the Zacks Consensus Estimate of a loss of $0.32 per share, and showing improvement from a loss of $0.41 per share a year ago, resulting in an earnings surprise of 146.88% [1] - The company achieved revenues of $30.85 million for the quarter ended December 2023, surpassing the Zacks Consensus Estimate by 346.89%, compared to revenues of $2.78 million in the same quarter last year [1] - Over the last four quarters, Alpine Immune Sciences has consistently surpassed consensus EPS and revenue estimates [1] 分组2 - Since the beginning of the year, Alpine Immune Sciences' shares have increased by approximately 90.9%, significantly outperforming the S&P 500's gain of 7.3% [2] - The company's current consensus EPS estimate for the upcoming quarter is -$0.29 on revenues of $7.17 million, and for the current fiscal year, it is -$1.55 on revenues of $31.3 million [4] - The Medical - Drugs industry, to which Alpine Immune Sciences belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [5]